Table 1.
List of currently ongoing clinical trials combining drugs targeting cell metabolism with immunotherapy strategies.
| Metabolic target | Drug targeting metabolism | Immunotherapy strategy | Tumor type | ClinicalTrials reference |
|---|---|---|---|---|
| IDO1 | BMS-986205 | nivolumab (anti-PD1)/ipilimumab (anti-CTLA4) | Melanoma Non-Small Cell Lung Cancer | NCT02658890 |
| epacadostat | BN-Brachyury (MVA-BN-Brachyury based cancer vaccine) | Prostate Cancer | NCT03493945 | |
| epacadostat | durvalumab (anti-PD-L1) | EBV+ Nasopharyngeal Cancer | NCT04231864 | |
| INCB001158 plus epacadostat | pembrolizumab (anti-PD1) | Solid Tumors | NCT03361228 | |
| Arginase | INCB001158 | pembrolizumab (anti-PD1) | Solid Tumors | NCT02903914 |
| Glutaminase | telaglenastat (CB-839) | pembrolizumab (anti-PD1) | Non-Small Cell Lung Carcinoma | NCT04265534 |
| AMPK | metformin | nivolumab (anti-PD1) | Non-Small Cell Lung Carcinoma | NCT03048500 |
| metformin | nivolumab (anti-PD1) | Colorectal Adenocarcinoma | NCT03800602 | |
| metformin | sintilimab (anti-PD1) | Small Cell Lung Carcinoma | NCT03994744 |
Details on clinical trial design can be found on https://clinicaltrials.gov/.